These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 15211328)

  • 41. Naturally occurring and bioengineered apoA-I mutations that inhibit the conversion of discoidal to spherical HDL: the abnormal HDL phenotypes can be corrected by treatment with LCAT.
    Koukos G; Chroni A; Duka A; Kardassis D; Zannis VI
    Biochem J; 2007 Aug; 406(1):167-74. PubMed ID: 17506726
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tangier disease: epidemiology, pathophysiology, and management.
    Puntoni M; Sbrana F; Bigazzi F; Sampietro T
    Am J Cardiovasc Drugs; 2012 Oct; 12(5):303-11. PubMed ID: 22913675
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel therapies to increase apolipoprotein AI and HDL for the treatment of atherosclerosis.
    Wong NC
    Curr Opin Investig Drugs; 2007 Sep; 8(9):718-28. PubMed ID: 17729183
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A selective peroxisome proliferator-activated receptor δ agonist PYPEP suppresses atherosclerosis in association with improvement of the serum lipoprotein profiles in human apolipoprotein B100 and cholesteryl ester transfer protein double transgenic mice.
    Naya N; Fukao K; Nakamura A; Hamada T; Sugimoto M; Kojima M; Yoshimura N; Uwabe K; Imagawa K; Nomura K; Hara S; Nakano T; Iwasaki T; Shinosaki T; Hanasaki K
    Metabolism; 2016 Jan; 65(1):16-25. PubMed ID: 26683793
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
    Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cholesterol reduction and atherosclerosis inhibition by bezafibrate in low-density lipoprotein receptor knockout mice.
    Inaba T; Yagyu H; Itabashi N; Tazoe F; Fujita N; Nagashima S; Okada K; Okazaki M; Furukawa Y; Ishibashi S
    Hypertens Res; 2008 May; 31(5):999-1005. PubMed ID: 18712055
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reverse cholesterol transport in type 2 diabetes mellitus.
    Tan KC
    Diabetes Obes Metab; 2009 Jun; 11(6):534-43. PubMed ID: 19175378
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Substitutions of glutamate 110 and 111 in the middle helix 4 of human apolipoprotein A-I (apoA-I) by alanine affect the structure and in vitro functions of apoA-I and induce severe hypertriglyceridemia in apoA-I-deficient mice.
    Chroni A; Kan HY; Kypreos KE; Gorshkova IN; Shkodrani A; Zannis VI
    Biochemistry; 2004 Aug; 43(32):10442-57. PubMed ID: 15301543
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HDL elevators and mimetics--emerging therapies for atherosclerosis.
    Pal M; Pillarisetti S
    Cardiovasc Hematol Agents Med Chem; 2007 Jan; 5(1):55-66. PubMed ID: 17266548
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Health benefits of high-density lipoproteins in preventing cardiovascular diseases.
    Berrougui H; Momo CN; Khalil A
    J Clin Lipidol; 2012; 6(6):524-33. PubMed ID: 23312048
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects: a potential novel therapeutic target in cardiovascular disease.
    Besler C; Heinrich K; Riwanto M; Lüscher TF; Landmesser U
    Curr Pharm Des; 2010 May; 16(13):1480-93. PubMed ID: 20196740
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Emerging role of high-density lipoprotein in the prevention of cardiovascular disease.
    Brousseau ME
    Drug Discov Today; 2005 Aug; 10(16):1095-101. PubMed ID: 16182194
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High-density Lipoprotein and Low-density Lipoprotein Therapeutic Approaches in Acute Coronary Syndromes.
    Androulakis E; Zacharia E; Papageorgiou N; Lioudaki E; Bertsias D; Charakida M; Siasos G; Tousoulis D
    Curr Cardiol Rev; 2017; 13(3):168-182. PubMed ID: 28190386
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Formation of dysfunctional high-density lipoprotein by myeloperoxidase.
    Nicholls SJ; Zheng L; Hazen SL
    Trends Cardiovasc Med; 2005 Aug; 15(6):212-9. PubMed ID: 16182131
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Therapeutic interventions targeted at the augmentation of reverse cholesterol transport.
    Toth PP; Davidson MH
    Curr Opin Cardiol; 2004 Jul; 19(4):374-9. PubMed ID: 15218399
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dysfunctional high-density lipoprotein and the potential of apolipoprotein A-1 mimetic peptides to normalize the composition and function of lipoproteins.
    Imaizumi S; Navab M; Morgantini C; Charles-Schoeman C; Su F; Gao F; Kwon M; Ganapathy E; Meriwether D; Farias-Eisner R; Fogelman AM; Reddy ST
    Circ J; 2011; 75(7):1533-8. PubMed ID: 21628835
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High-Density Lipoproteins: Biology, Epidemiology, and Clinical Management.
    Choi HY; Hafiane A; Schwertani A; Genest J
    Can J Cardiol; 2017 Mar; 33(3):325-333. PubMed ID: 28063740
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HDL cholesterol and protective factors in atherosclerosis.
    Assmann G; Gotto AM
    Circulation; 2004 Jun; 109(23 Suppl 1):III8-14. PubMed ID: 15198960
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cradle-to-grave atherosclerosis: high density lipoprotein cholesterol.
    Glueck CJ
    J Am Coll Nutr; 1982; 1(1):41-8. PubMed ID: 7185843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.